Caelum Biosciences announces positive phase 1a/1b data for CAEL-101 (mAb 11-1F4)
Caelum Biosciences announced full Phase 1a/1b clinical data demonstrating CAEL-101’s (mAb 11-1F4) ability to bind to light-chain amyloid fibrils and achieve early and clinically efficacious organ responses in patients with relapsed and refractory amyloid light chain amyloidosis. December 11, 2017